
Apellis Pharmaceuticals APLS
Apellis Pharmaceuticals Operating Cash Flow | APLS
Annual Operating Cash Flow Apellis Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.3 M | -87.9 M | -595 M | -514 M | -563 M | -160 M | -211 M | -131 M | -46.6 M | -26 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45.3 M | -595 M | -229 M |
Quarterly Operating Cash Flow Apellis Pharmaceuticals
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -61 M | -14.2 M | 108 M | 4.44 M | -53.4 M | - | 34.1 M | -8.34 M | -133 M | -97.9 M | -169 M | -150 M | -178 M | -141 M | -154 M | -107 M | -112 M | -112 M | -169 M | -129 M | -153 M | 142 M | -99.8 M | -94.3 M | -108 M | -82.1 M | -53.6 M | -39.9 M | -35.6 M | -44.5 M | -33.1 M | -30.7 M | -22.9 M | -15.5 M | -31.1 M | -19.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 142 M | -178 M | -67.5 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Brickell Biotech
BBI
|
-4.34 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
-84.3 M | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
-22.7 M | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
-88.6 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
-24.7 M | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
-186 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
-83.3 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
-186 M | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
-8.87 M | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
-257 M | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-630 K | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
-1.83 M | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-6.32 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
-49.5 M | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
-43.9 M | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
-31.1 M | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
-48.6 M | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
-69.6 M | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
-47.2 M | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
-1.21 B | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
-269 M | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
-17.8 M | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
-24.5 M | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
-122 M | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
-80.7 M | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
-4.37 M | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
1.93 M | - | - | $ 109 M | ||
|
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
-230 M | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
-13.7 M | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
-177 M | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
-26.8 M | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
-16.7 M | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
-8.99 M | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
-45 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
-32.1 M | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
-260 M | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
-20.5 M | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
-21.1 M | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
-46 M | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
-51.5 M | - | - | $ 728 M | ||
|
Regulus Therapeutics
RGLS
|
-41.7 M | - | - | $ 155 M | ||
|
NGM Biopharmaceuticals
NGM
|
-132 M | - | - | $ 127 M | ||
|
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
-378 M | $ 84.95 | 0.13 % | $ 7.99 B |